|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine显示文摘 | Keith T. Flaherty James P. Stevenson Maryann Redlinger Kenneth M. Algazy Bruce Giantonio Peter J. O’Dwyer | 2004 | Cancer Chemotherapy and Pharmacology2004，，5： | 1 |
| 2 | Bevacizumab incombination with oxaliplatin, fluorouracil, and leucovorin (FOL2FOX4) for previously treated metastatic coloreetal cancer:resultsfrom the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio B J Catalano P J Meropol NJ | 2007 | J Clin Oncol2007，25，12： | 1 |
| 3 | Bevacizumab in combination with oxaliplatin fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | | 0，，12： | 1 |
| 4 | Superantigen-based immunotherapy: a phase I trial ofPNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer显示文摘 | Giantonio BJ Alpaugh RK Schultz J | 1997 | J Clin Oncol1997，15，5： | 1 |
| 5 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘 | GIANTONIO B J CATALANO P J MEROPOL N J | 2007 | J Clin Oncol2007，25，12： | 1 |
| 6 | Evaluating antiangiogenesis agents in the clinic:the Eastern Cooperative Oncology Group Portfolio of Clinical Trials显示文摘 | Sparano JA Gray R Giantonio B | 2004 | Clin Cancer Res2004，10，4： | 1 |
| 7 | Bevacizumab in combi- nation with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2007 | J Clin Oncol2007，25，12： | 1 |
| 8 | Bevaeizumab in combination with oxaliplatin, fluorouracil, and leucovorin ( FOL- FOX4) for previously treated metastatic colorectal cancer: Results from the Easterm Cooprative Oneology Group Study E3200 显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2007 | J Clin Oneol2007，25，12： | 1 |
| 9 | Bevacizumab in combination with oxaliplatin,fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | | 0，，12： | 1 |
| 10 | hnpact of bevaeizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oneology Group's Study E3200显示文摘 | Giantonio B J Catalano PJ O'Dwyer P J | 2006 | Proc Am Soc Clin Oncol2006，24，18： | 1 |
| 11 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio B J Catalano P J Meropol N J | 2007 | J ClinOncol2007，25，12： | 1 |
| 12 | High-dose bevacizumab improyes survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2005 | J Clin Oneol2005，23，： | 1 |
| 13 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2007 | J Clin Oncol2007，25，： | 1 |
| 14 | Bevacizumab: current indications and future development for management of solid tumors显示文摘 | Jenab-Wolcott J Giantonio BJ | 2009 | Expert Opin Biol Ther2009，9，： | 1 |
| 15 | High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer:Results from the Eastern Cooperative Oncology Group (ECOG) study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2005 | Pro Am Soc Clin Oncol2005，23，： | 1 |
| 16 | High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group(ECOG) study E3200 (abstract2) 显示文摘 | Giantonio B J Catalano PJ Meropol N J | 2005 | J Clin Oncol2005，23，16： | 1 |
| 17 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘 | Giantonio B J Catalano P J Meropol N J | 2007 | J Ctin Oncol2007，25，12： | 1 |
| 18 | A phase Ⅱ study of high-dose bevacizumab in combination with irinotecan,5-fluoroura-cil,leucovorin,as initial therapy for advanced colorectal cancer:re-sults from the Eastern Cooperative Oncology Group study E2200显示文摘 | Giantonio BJ Ley DE O'dwyer PJ | 2006 | Ann Oncol2006，17，9： | 1 |
| 19 | Bevacizumab in com-bination with oxaliplatin,fluorouracil,and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer;results from the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2007 | J Clin On-col2007，25，12： | 1 |
| 20 | Bevacizumab in combina-tion with oxaliplatin,fluorouracil,and leucovorin(FOLFOX4)for previ-ously treated metastatic colorectal cancer:results from the Eastern Co-operative Oncology Group Study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员